---
$id: https://graph.org.ai/products/commodity/51112010
$type: Product
source: UNSPSC
code: "51112010"
title: "Vandetanib"
class: "51112000"
classTitle: "Tyrosine kinase inhibitors"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Vandetanib

**UNSPSC Code**: 51112010
**Class**: [Tyrosine kinase inhibitors](Tyrosine kinase inhibitors.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H24BrFN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YO460OQ37K, chemically known as 4-quninazolinamine, n-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)- but generally known as vandetanib, which bears US NIH Compound Identifier 3081361. European Medicines Agency schedules Vandetanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB29174. The term VANDETANIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19, No. 1, 2005, List 53). World Health Organization schedules vandetanib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule vandetanib under HS 29335995 and SITC 51576. As of Q4 2014, VANDETANIB remains the US FDA Preferred Term for this commodity. Vandetanib bears US NLM identifiers UMLS ID C1384659 and NCI Concept Code C2737. SMILES: BRC1CC(F)C(NC2NCNC3CC(OCC4CCN(CC4)C)C(OC)CC23)CC1.

